Speaker Profile

M.D., CEO, incellDx

Bruce Patterson studied molecular biology at the University of Michigan. He then received his MD at Northwestern University followed by a residency in pathology. During the early stages of the AIDS epidemic, Dr. Patterson began investigating cellular reservoirs of HIV-1 using molecular and in situ cell based technology patented in his laboratory and used today around the world. Dr. Patterson determined that enough HIV virus was present in infected individuals to account for the massive destruction of the immune system. This paradigm altering work was published in 1993 and featured in Scientific American, Rolling Stone, and on the Discovery Channel. Dr. Patterson has authored over 150 manuscripts and book chapters focusing on single cell biology and diagnostics. Dr. Patterson was formerly Associate Professor of Pathology and Infectious Diseases and Director of Virology at Stanford University. He has translated his research discoveries into single cell diagnostics for Cancer, Immuno-Oncology, and Infectious Diseases.

Targeting CCL5/CCR5 In COVID-19
In Critical COVID-19 patients, we observed complete CCR5 receptor occupancy concomitant with a statistically significant reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and resolution of SARS-CoV-2 plasma following leronlimab (anti-CCR5 MAB) therapy. Single-cell RNA-sequencing revealed transcriptomic declines of IL-6 responsive genes and interferon-related genes in myeloid cells.